1. Belgium Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Galapagos N.V.

Galapagos N.V.

GLPGF
Galapagos N.V.US flagOther OTC
28.08
USD
- -
- -
1.85BMarket Cap
Galapagos N.V.
GLPGF
(Other OTC)

Recent

price

28.08

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
5.04
3.63
5.13
2.66
2.3
1.11
2.83
2.57
5.35
14.49
7.35
3.58
3.67
3.64
4.17
16.88
15.84
Revenue per Share
0.18
-1.25
-0.22
-0.28
1.1
-3.32
1.18
-2.34
-0.56
2.6
-4.69
-1.58
-3.32
3.21
1.12
4.87
7.42
Basic EPS, GAAP
-0.94
-0.68
2.16
-0.21
-2.6
-3.4
5.13
-3.12
-3
54.9
-7.97
-8.58
-8.19
-6.45
-6.08
-4.12
-4.71
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
3.17
1.75
1.68
1.89
3.1
0.23
2.44
0.44
-1.18
3.09
-0.67
-1.15
-3.09
1
2.41
7.66
7.93
Book Value per Share
3.81
2.61
2.69
4.17
6.78
10.18
16.58
20.4
23.23
49.48
40
39.44
35.18
39.43
40.25
49.09
49.38
Tangible Book Value per Share
24
26
27
29
30
36
46
49
52
58
65
66
66
66
66
66
66
Basic Weighted Avg Shares
122
96
136
77
69
40
130
127
279
835
478
234
241
240
276
1,112
1,044
Sales/Revenue/Turnover
1.2
-36.59
-1.54
-21.69
-51.83
-226.09
-8.87
-70.66
-16.89
44.17
-37.37
-73.2
-54.32
-36.82
-68.33
45.08
57.14
Operating Margin (%)
12
12
9
8
5
3
4
4
5
12
19
35
66
44
45
56
- -
Depreciation Expense
4
-33
-6
-8
33
-118
54
-116
-29
150
-305
-103
-218
212
74
321
489
Net Income, GAAP
- -
- -
- -
- -
- -
- -
0.43
- -
- -
- -
- -
- -
- -
170.9
- -
- -
0.59
Effective Tax Rate (%)
3.57
-34.52
-4.2
-10.54
47.88
-299.3
41.7
-91.04
-10.5
17.95
-63.89
-44.04
-90.36
88.31
26.88
28.85
46.83
Profit Margin (%)
71
30
24
61
153
302
903
1,026
1,109
5,294
4,734
4,295
3,714
3,433
3,004
2,927
2,960
Working Capital
1
- -
- -
- -
- -
- -
- -
- -
- -
20
23
20
15
5
8
5
5
LT Debt
149
118
118
167
206
365
759
1,012
1,214
2,876
2,670
2,643
2,526
2,796
2,897
3,236
3,253
Total Equity
- -
- -
- -
- -
- -
- -
-2.03
- -
- -
- -
- -
- -
- -
2.34
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
90.16
- -
- -
- -
- -
- -
- -
-397.34
- -
- -
270.87
Return on Capital (%)
6.57
-53.66
-12.59
-16.32
44.95
-233.52
90.22
-173.17
- -
- -
- -
- -
- -
- -
65.76
96.63
182.59
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
2
2
2
LT Borrowings
- -
- -
- -
LT Finance Leases
6
5
5
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
66
66
66
Market Capitalization
1,877
1,754
1,897

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
3,162
3,079
3,061
Cash, Cash Equivalents & STI
3,050
2,998
2,982
Accounts Receivable, Net
45
10
22
Inventories
23
22
18
Total Current Liabilities
367
153
100
Payables & Accruals
101
34
97
ST Debt
2
2
2
Deferred Revenue
230
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
31.15%
4.11%
11.7%
Free Cash Flow
-275.46%
-10.97%
-32.53%
Net Income, GAAP
-133.45%
23.2%
333.15%
Sales/Revenue/Turnover
77.15%
53.96%
303.5%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
62
78
60
75
276
2025
75
65
71
901
1,112
2026
6
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.37
- -
- -
- -
1.12
2025
-2.33
- -
- -
- -
4.87
2026
0.22
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Marker Therapeutics, Inc. (MRKR)
Cellectis S.A. (CLLS)
Pharvaris N.V. (PHVS)
NRx Pharmaceuticals, Inc. (NRXP)
Newron Pharmaceuticals S.p.A. (NWRN.SW)
SK Biopharmaceuticals Co., Ltd. (326030.KS)
Business
Galapagos NV (Euronext & NASDAQ: GLPG) is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize small molecule, biologic and cell therapy medicines addressing high unmet medical needs in oncology and immunology; its core offerings include an early-stage pipeline of next-generation precision small molecules such as the selective TYK2 inhibitor GLPG3667 in Phase 2 for systemic lupus erythematosus and dermatomyositis; decentralized, point-of-care CAR-T cell therapies including GLPG5201 (CD19 CAR-T) in Phase 1/2 for relapsed/refractory chronic lymphocytic leukemia and Richter transformation, GLPG5101 (CD19 CAR-T) in Phase 1/2 for relapsed/refractory non-Hodgkin lymphoma, and GLPG5301 (BCMA CAR-T) in Phase 1/2 for relapsed/refractory multiple myeloma; and proprietary human antibody libraries for multi-specific CAR-Ts and biologics discovered through fully human formats including Fab, scFv and VH domains. The company operates from its headquarters in Mechelen, Belgium, where it was founded in 1999 as a joint venture between Crucell and Tibotec, with additional facilities in the Netherlands, France, Switzerland, the United States and other locations across Europe and Asia; it maintains approximately 700 employees focused on end-to-end R&D capabilities encompassing chemical library development, high-throughput screening, pharmacology, preclinical development and decentralized manufacturing via platforms like xCellit software, Lonza’s Cocoon system and proprietary quality control for fresh, fit CAR-T cells with a median seven-day vein-to-vein time. In recent strategic developments, Galapagos completed the transfer of its Jyseleca (filgotinib) business to Alfasigma S.p.A. in January 2024, including European and UK marketing authorizations, commercial activities and approximately 400 positions; entered a strategic collaboration and license agreement with BridGene Biosciences to bolster its early-stage oncology precision medicine pipeline; signed a collaboration with Thermo Fisher Scientific for CAR-T manufacturing and kitting services; and in October 2025 announced its intention to wind down the cell therapy business following a strategic review that attracted limited non-binding offers from financial investors, with a decision expected by early November 2025 alongside Q3 financial results; it also amended its filgotinib agreement with Gilead Sciences to end cost-sharing and royalty obligations, participated in Series C financing of Frontier Medicines for precision oncology assets, and continues seeking partners for small molecule assets while advancing clinical programs and external innovation through M&A and partnerships.

Company News

APIChatGPT

  • seekingalpha.com

    Galapagos NV (GLPG) Q1 2026 Earnings Call Transcript

  • https://thefly.com

    Deutsche Bank downgrades Galapagos to Sell amid 'too much uncertainty'